120 related articles for article (PubMed ID: 15692602)
21. Complications of beta-thalassemia major in North America.
Cunningham MJ; Macklin EA; Neufeld EJ; Cohen AR;
Blood; 2004 Jul; 104(1):34-9. PubMed ID: 14988152
[TBL] [Abstract][Full Text] [Related]
22. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
[TBL] [Abstract][Full Text] [Related]
23. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
Haghpanah S; Zarei T; Zahedi Z; Karimi M
Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
[TBL] [Abstract][Full Text] [Related]
24. Pituitary iron and volume predict hypogonadism in transfusional iron overload.
Noetzli LJ; Panigrahy A; Mittelman SD; Hyderi A; Dongelyan A; Coates TD; Wood JC
Am J Hematol; 2012 Feb; 87(2):167-71. PubMed ID: 22213195
[TBL] [Abstract][Full Text] [Related]
25. Advances in the use of iron-chelating agents for the treatment of iron overload.
Modell B
Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
[No Abstract] [Full Text] [Related]
26. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
27. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
28. Desferrioxamine ototoxicity in an adult transfusion-dependent population.
Chiodo AA; Alberti PW; Sher GD; Francombe WH; Tyler B
J Otolaryngol; 1997 Apr; 26(2):116-22. PubMed ID: 9106087
[TBL] [Abstract][Full Text] [Related]
29. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
30. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.
Di Marco V; Capra M; Gagliardotto F; Borsellino Z; Cabibi D; Barbaria F; Ferraro D; Cuccia L; Ruffo GB; Bronte F; Di Stefano R; Almasio PL; Craxì A
Haematologica; 2008 Aug; 93(8):1243-6. PubMed ID: 18556410
[TBL] [Abstract][Full Text] [Related]
31. Progression of iron overload in sickle cell disease.
Olivieri NF
Semin Hematol; 2001 Jan; 38(1 Suppl 1):57-62. PubMed ID: 11206962
[TBL] [Abstract][Full Text] [Related]
32. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
33. Iron overload and chronically transfused patients: numbers, scales, and clinical research.
Callea F
Am J Hematol; 2009 Aug; 84(8):471-2. PubMed ID: 19565648
[No Abstract] [Full Text] [Related]
34. Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia.
Flanagan JM; Steward S; Hankins JS; Howard TM; Neale G; Ware RE
Am J Hematol; 2009 Jun; 84(6):328-34. PubMed ID: 19384939
[TBL] [Abstract][Full Text] [Related]
35. High-dose intravenous chelation therapy with deferoxamine.
Cohen A; Mizanin J; Schwartz E
Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
[No Abstract] [Full Text] [Related]
36. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
Pakbaz Z; Fischer R; Treadwell M; Yamashita R; Fung EB; Calvelli L; Quirolo K; Foote D; Harmatz P; Vichinsky EP
Ann N Y Acad Sci; 2005; 1054():486-91. PubMed ID: 16339703
[TBL] [Abstract][Full Text] [Related]
37. Methods for noninvasive measurement of tissue iron in Cooley's anemia.
Sheth S; Tang H; Jensen JH; Altmann K; Prakash A; Printz BF; Hordof AJ; Tosti CL; Azabagic A; Swaminathan S; Brown TR; Olivieri NF; Brittenham GM
Ann N Y Acad Sci; 2005; 1054():358-72. PubMed ID: 16339684
[TBL] [Abstract][Full Text] [Related]
38. Severe iron overload in Blackfan-Diamond anemia: a case-control study.
Roggero S; Quarello P; Vinciguerra T; Longo F; Piga A; Ramenghi U
Am J Hematol; 2009 Nov; 84(11):729-32. PubMed ID: 19810012
[TBL] [Abstract][Full Text] [Related]
39. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.
Aldouri MA; Wonke B; Hoffbrand AV; Flynn DM; Laulicht M; Fenton LA; Scheuer PJ; Kibbler CC; Allwood CA; Brown D
J Clin Pathol; 1987 Nov; 40(11):1353-9. PubMed ID: 3121679
[TBL] [Abstract][Full Text] [Related]
40. Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age.
Berdoukas V; Nord A; Carson S; Puliyel M; Hofstra T; Wood J; Coates TD
Am J Hematol; 2013 Nov; 88(11):E283-5. PubMed ID: 23861216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]